203 related articles for article (PubMed ID: 26611352)
1. Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo.
Harun R; Hare KM; Brough EM; Munoz MJ; Grassi CM; Torres GE; Grace AA; Wagner AK
J Neurochem; 2016 Mar; 136(6):1270-1283. PubMed ID: 26611352
[TBL] [Abstract][Full Text] [Related]
2. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.
De Deurwaerdère P; Di Giovanni G; Millan MJ
Prog Neurobiol; 2017 Apr; 151():57-100. PubMed ID: 27389773
[TBL] [Abstract][Full Text] [Related]
3. Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Tseng KY; Kuo TT; Wang V; Huang EY; Ma KH; Olson L; Hoffer BJ; Chen YH
J Parkinsons Dis; 2022; 12(5):1545-1565. PubMed ID: 35599497
[TBL] [Abstract][Full Text] [Related]
4. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
5. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Eskow Jaunarajs KL; George JA; Bishop C
Neuroscience; 2012 Aug; 218():243-56. PubMed ID: 22659568
[TBL] [Abstract][Full Text] [Related]
6. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
[TBL] [Abstract][Full Text] [Related]
7. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
[TBL] [Abstract][Full Text] [Related]
8. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Bishop C
Behav Brain Res; 2014 Aug; 270():75-85. PubMed ID: 24837745
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats.
Zheng CQ; Fan HX; Li XX; Li JJ; Sheng S; Zhang F
Front Immunol; 2021; 12():683577. PubMed ID: 34248967
[TBL] [Abstract][Full Text] [Related]
10. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Bishop C; George JA; Buchta W; Goldenberg AA; Mohamed M; Dickinson SO; Eissa S; Eskow Jaunarajs KL
Eur J Neurosci; 2012 Sep; 36(6):2839-48. PubMed ID: 22762478
[TBL] [Abstract][Full Text] [Related]
11. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
Chotibut T; Fields V; Salvatore MF
Mol Pharmacol; 2014 Dec; 86(6):675-85. PubMed ID: 25208966
[TBL] [Abstract][Full Text] [Related]
12. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
[TBL] [Abstract][Full Text] [Related]
13. Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA.
Lettfuss NY; Fischer K; Sossi V; Pichler BJ; von Ameln-Mayerhofer A
Neuroimage; 2012 Oct; 63(1):423-33. PubMed ID: 22766162
[TBL] [Abstract][Full Text] [Related]
14. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
[TBL] [Abstract][Full Text] [Related]
15. Striatal norepinephrine efflux in l-DOPA-induced dyskinesia.
Ostock CY; Bhide N; Goldenberg AA; George JA; Bishop C
Neurochem Int; 2018 Mar; 114():85-98. PubMed ID: 29371053
[TBL] [Abstract][Full Text] [Related]
16. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
17. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
Albarrán-Bravo S; Ávalos-Fuentes JA; Cortés H; Rodriguez-Sánchez M; Leyva-García N; Rangel-Barajas C; Erlij D; Florán B
Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480516
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
19. Dual effects of L-DOPA on nigral dopaminergic neurons.
Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
[TBL] [Abstract][Full Text] [Related]
20. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
